Efficacy and tolerability of coenzyme A vs pantethine for the treatment of patients with hyperlipidemia: A randomized, double-blind, multicenter study

Journal of Clinical Lipidology
Ya-qin ChenYu-Hong Zhao

Abstract

New, safer, and more effective agents to treat hyperlipidemia and thereby prevent cardiovascular events are under research. To evaluate the lipid-lowering effects and safety of a natural hypolipidemic compound, coenzyme A (CoA) capsule, in Chinese patients with moderate dyslipidemia, compared with pantethine. Overall, 216 subjects (124 males and 92 females; age, 18-75 years) with moderate dyslipidemia (triglyceride [TG], 2.3-6.5 mmol/L) were randomly divided into 2 groups administered CoA 400 U/d (n = 111) or pantethine 600 U/d (n = 105). Blood lipoproteins, liver and renal function, blood glucose, and complete blood count were measured at baseline and after 4- and 8-week treatment. TG reduction was 26.0% with CoA and 17.4% with pantethine after 4 weeks and 33.3% and 16.5% after 8 weeks; compared with baseline, the reduction was significant (P < .01) in both groups. The difference between the 2 groups was significant at both 4 weeks (P = .0413) and 8 weeks (P < .001). Compared with baseline, total cholesterol and non-high-density lipoprotein cholesterol (non-HDL-C) were reduced, whereas HDL-C was increased with CoA after 8 weeks (all P < .05). Compared with pantethine, total cholesterol (P = .026) and non-HDL-C (P = .005) were ...Continue Reading

References

May 23, 2001·JAMA : the Journal of the American Medical Association·UNKNOWN Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults
Mar 30, 2002·The Journal of Biological Chemistry·Matthew DaughertyAndrei Osterman
Jun 17, 2009·Circulation·P Michael HoJohn S Rumsfeld
Mar 23, 2011·Expert Opinion on Drug Safety·Michel Farnier
Apr 20, 2011·Circulation·Michael MillerUNKNOWN Council on the Kidney in Cardiovascular Disease
Jan 8, 2013·The Journal of Clinical Endocrinology and Metabolism·Ya-qin ChenJiangtao Lai

❮ Previous
Next ❯

Citations

Sep 6, 2017·Analytical and Bioanalytical Chemistry·Toomas PaalmeKristel Hälvin-Tanilas
Jul 4, 2019·Neurotherapeutics : the Journal of the American Society for Experimental NeuroTherapeutics·Kevin BarangerPhilippe Benech
Apr 10, 2019·Proceedings of the National Academy of Sciences of the United States of America·Julia I-Ju LeuDonna L George
Aug 19, 2018·Journal of Orthopaedic Surgery and Research·Yang Yang, Jin Qu
Dec 3, 2020·International Journal of Molecular Sciences·Aleksandra CzumajEwa Stelmanska

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiovascular Disease Pathophysiology

Cardiovascular disease involves several different processes that contribute to the pathological mechanism, including hyperglycemia, inflammation, atherosclerosis, hypertension and more. Vasculature stability plays a critical role in the development of the disease. Discover the latest research on cardiovascular disease pathophysiology here.

ApoE, Lipids & Cholesterol

Serum cholesterol, triglycerides, apolipoprotein B (APOB)-containing lipoproteins (very low-density lipoprotein (VLDL), immediate-density lipoprotein (IDL), and low-density lipoprotein (LDL), lipoprotein A (LPA)) and the total cholesterol/high-density lipoprotein (HDL) cholesterol ratio are all connected in diseases. Here is the latest research.